Page last updated: 2024-08-24

telmisartan and Bone Loss, Perimenopausal

telmisartan has been researched along with Bone Loss, Perimenopausal in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ding, LJ; Huang, QJ; Ji, H; Li, YQ; Shen, Y; Yang, YL; Zhuang, P	1

Other Studies

1 other study(ies) available for telmisartan and Bone Loss, Perimenopausal

Article	Year
Chronic treatment with angiotensin AT1 receptor antagonists reduced serum but not bone TGF-beta1 levels in ovariectomized rats. Canadian journal of physiology and pharmacology, 2009, Volume: 87, Issue:1 Topics: Acid Phosphatase; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Bone and Bones; Bone Density; Female; Humans; Isoenzymes; Osteocalcin; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Tartrate-Resistant Acid Phosphatase; Telmisartan; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan	2009

Article

Year

Chronic treatment with angiotensin AT1 receptor antagonists reduced serum but not bone TGF-beta1 levels in ovariectomized rats.

Canadian journal of physiology and pharmacology, 2009, Volume: 87, Issue:1

Topics: Acid Phosphatase; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Bone and Bones; Bone Density; Female; Humans; Isoenzymes; Osteocalcin; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Tartrate-Resistant Acid Phosphatase; Telmisartan; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan

2009